Table 1.
Association between KRT8 expression and clinicopathologic features in the TCGA cohort of LUAD.
| Characteristic | Low expression of KRT8 (n = 267) | High expression of KRT8 (n = 268) | p |
|---|---|---|---|
| T stage, n (%) | 0.010 | ||
| T1 | 104 (19.5%) | 71 (13.3%) | |
| T2 | 134 (25.2%) | 155 (29.1%) | |
| T3 | 18 (3.4%) | 31 (5.8%) | |
| T4 | 10 (1.9%) | 9 (1.7%) | |
| N stage, n (%) | 0.028 | ||
| N0 | 185 (35.6%) | 163 (31.4%) | |
| N1 | 42 (8.1%) | 53 (10.2%) | |
| N2 | 27 (5.2%) | 47 (9.1%) | |
| N3 | 1 (0.2%) | 1 (0.2%) | |
| M stage, n (%) | 0.594 | ||
| M0 | 172 (44.6%) | 189 (49%) | |
| M1 | 10 (2.6%) | 15 (3.9%) | |
| Pathologic stage, n (%) | 0.025 | ||
| Stage I | 162 (30.7%) | 132 (25%) | |
| Stage II | 56 (10.6%) | 67 (12.7%) | |
| Stage III | 32 (6.1%) | 52 (9.9%) | |
| Stage IV | 11 (2.1%) | 15 (2.8%) | |
| Age, n (%) | 0.094 | ||
| ≤65 | 117 (22.7%) | 138 (26.7%) | |
| >65 | 140 (27.1%) | 121 (23.4%) | |
| Gender, n (%) | 0.027 | ||
| Female | 156 (29.2%) | 130 (24.3%) | |
| Male | 111 (20.7%) | 138 (25.8%) | |
| Smoker, n (%) | 0.465 | ||
| No | 41 (7.9%) | 34 (6.5%) | |
| Yes | 220 (42.2%) | 226 (43.4%) |